Actinium
Pharmaceuticals,Inc.
ATNM: NYSE AMERICAN
November 2020
Disclaimer and Safe Harbor
The information presented herein contains express and implied forward-looking statements regarding the current intentions, expectations, estimates, opinions and beliefs of Actinium Pharmaceuticals, Inc. ("Actinium") that are not historical facts. These forward- looking statements include statements regarding Actinium's expectations for its product candidates (including their therapeutic and commercial potential, anticipated future development activities, anticipated timing of development activities, including initiation of clinical trials and presentations of clinical data and the indications Actinium and its collaborators plan to pursue), future results of operations and financial position, business strategy, strategic collaborations, any royalty or milestone payments and Actinium's ability to obtain and maintain intellectual property protection for its product candidates. Such forward-looking statements may be identified by words such as "believes", "may", "will", "expects", "endeavors", "anticipates", "intends", "plans", "estimates", "projects", "should", "objective" and variations of such words and similar words. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on Form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.
Any forward-looking statements that Actinium makes in this presentation speak only as of the date of this presentation. Except as required by law, Actinium assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date hereof. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by Actinium or any director, employee, agent, or adviser of Actinium. This presentation does not purport to be all-inclusive or to contain all of the information you may desire. The content of this presentation is subject to copyright, which will be asserted by Actinium, and no part of this presentation may be reproduced, stored in a retrieval system, or transmitted in any form or by any means without prior permission in writing from Actinium.
Actinium | |
Pharmaceuticals | 2 |
Company Highlights
Late-stage, diverse Antibody Radiation-Conjugate (ARC) pipeline is maturing and progressing toward
topline pivotal, POC trial and platform data amidst growing interest for targeted radiotherapies
Pivotal Phase 3 SIERRA trial for lead program, Iomab-B, showing clear value proposition for BMT conditioning for AML with interim analysis in 4Q:2020
Leading next-generation targeted conditioning clinical-stage pipeline for Bone
Marrow Transplant (BMT), CAR-T and GeneTx
Actimab-A, CD33 targeting ARC advancing in multiple R/R AML combination trials including with CLAG-M and venetoclax, PoC data could set the stage for one or more pivotal trials
AWE technology platform drives innovation and future opportunities including partnerships, next-generation ARCs and solid tumor initiatives
Strong balance sheet with ~$48 million* enables multiple clinical and corporate milestones in 2020, 2021 including topline SIERRA and several POC trial results
Actinium | AML - Acute Myeloid Leukemia, MDS - Myelodysplastic Syndrome, MM - Multiple Myeloma | |
Pharmaceuticals | * as of September 30, 2020 | 3 |
AWE Platform Enables Pipeline, Future Opportunities
Our AWE technology platform allows us to create ARCs for multiple areas of clinical development
AWE Technology Platform | Areas of Focus | |||||
Scientific Founders | Linker Isotope | |||||
Targeted Conditioning | ||||||
§ Bone Marrow Transplant (BMT) | ||||||
Antibody | § | CAR-T and Adoptive Cell Therapy (ACT) | ||||
§ | GeneTx | |||||
§ | Two Pivotal Programs | |||||
Collaborators | ARC Therapeutics and | |||||
Combinations | ||||||
§ | Internalized targeted radiation | |||||
§ | Synergistic with chemotherapy, | |||||
Strong, Growing IP Portfolio of 100+ Patents | targeted agents and immunotherapy | |||||
Multiple Targets
CD45 | CD33 | CD38 |
Leukemia, Lymphoma | AML, MDS | MM and |
and immune cells | and MM | leukemia cells |
Multiple Isotopes(1) | ||
Iodine-131 | Actinium-225 | Lutetium-177 |
Range: 2.3 mm | Range: .048 mm | Range: 1.5 mm |
Energy: 0.6 MeV | Energy: 5.8 MeV | Energy: 0.47 MeV |
Other Near-Term Opportunities
Solid Tumors | Next-Generation ARCs |
Actinium
Pharmaceuticals | 1) Pouget J.-P.et al. Nat. Rev. Clin. Oncol. 8, 720-734 (2011); published online 8 November 2011. | 4 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Actinium Pharmaceuticals Inc. published this content on 11 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 November 2020 13:24:04 UTC